If pregnant or breastfeeding, consult your healthcare practitioner before use
Health Canada approves ZEPBOUND as the first-ever obstructive sleep apnea medication in Canada for adults living with obesity Averaging up to 20% of weight loss, adults taking ZEPBOUND had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking ZEPBOUND no longer had symptoms associated with OSA after one year TORONTO, June 16, 2026 /CNW/ - Eli Lilly Canada announced today that Health Canada has approved ZEPBOUND (tirzepatide injection) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity (BMI 30 kg/m2 or greater), to be used in combination with a reduced-calorie diet and increased physical activity
Further information is available on the NHS Diabetic Ketoacidosis (DKA) page
Plant Physiology 142, 775787
Cellular Pathways Creatine acts as an osmolyte via the CT1 transporter, increasing cell water and ATP production
Archives of General Psychiatry, 56(1), 29-36
